类细菌素的抗菌机制。
Antimicrobial mechanism of lantibiotics.
机构信息
Laboratory of Microbial Technology, Division of Applied Molecular Microbiology and Biomass Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Graduate School, Kyushu University, 6-10-1 Hakozaki, Fukuoka 812-8581, Japan.
出版信息
Biochem Soc Trans. 2012 Dec 1;40(6):1528-33. doi: 10.1042/BST20120190.
Lantibiotics are ribosomally synthesized antimicrobial peptides that commonly target the cell wall precursor lipid II during their antimicrobial mechanism and exert their inhibitory activity by (i) inhibition of cell wall biosynthesis, and (ii) stable pore formation in the target membrane. Type-A(I) (i.e. nisin) and two-component (i.e. lacticin 3147) lantibiotics initially interact with lipid II to stabilize the complex, which then proceeds to inhibit cell wall biosynthesis and pore formation. Type-A(II) (i.e. nukacin ISK-1) and type-B (i.e. mersacidin) lantibiotics also use lipid II as a docking molecule, but can only inhibit cell wall biosynthesis without forming pores. In the present paper, we review the antimicrobial mechanism of different types of lantibiotics, their current progress and future prospect.
类细菌素是核糖体合成的抗菌肽，通常在其抗菌机制中靶向细胞壁前体脂质 II，并通过以下两种方式发挥抑制活性：（i）抑制细胞壁生物合成；（ii）在靶膜中稳定形成孔。A 型（I）（如乳链菌肽）和双组分（如乳球菌素 3147）类细菌素最初与脂质 II 相互作用以稳定复合物，然后继续抑制细胞壁生物合成和孔形成。A 型（II）（如 nukacin ISK-1）和 B 型（如 mersacidin）类细菌素也将脂质 II 用作对接分子，但只能抑制细胞壁生物合成而不形成孔。在本文中，我们综述了不同类型类细菌素的抗菌机制、它们的研究进展和未来前景。
Zotero 插件